PCI Biotech: “A transformative year”
Our portfolio company PCI Biotech published their full year report for 2017 today.
Entries by Elisabeth K. Andersen
Podkasten Radium går live – og vi vil se deg!
Podkasten Radium forflytter seg ut av studioet i Oslo Cancer Cluster Innovasjonspark til Kreftforeningens Vitensenter to ganger nå i mars. Vi håper å se deg blant publikum! Sammen med Kreftforeningen arrangerer vi to live podkaster i mars. Se info om seminarene nedenfor: Investering med hode og hjertet Meld deg på her Temaet for live […]
Tidligere leder av Utprøvingsenheten, Steinar Aamdal, går til Ultimovacs
Vår porteføljebedrift Ultimovacs AS har nylig ansatt professor emeritus Steinar Aamdal som Senior Medical Adviser. Steinar Aamdal går nå av ved aldersgrensen for stillingen som overlege ved Avdeling for kreftbehandling ved Oslo universitetssykehus. Han har etablert og ledet Utprøvingsenheten på Radiumhospitalet som utfører tidlig-fase studier av nye kreftmedisiner. De senere år har han vært […]
Photocure: FDA approval for new indications
Photocure´s drug and device for detection of bladder cancer may also be used in the ongoing surveillance of afflicted patients.
– Productive year for Targovax
Overall, the prospects are great for 2018, says Øystein Soug in a press release from Targovax.
Prestigious BIA-funding to OncoImmunity and Oncoinvent
Two of our portfolio companies receive funding in though competition.
Oncoinvent with new production facility at Nydalen
Our portfolio company Oncoinvent opened brand-new lab and production facilities at Nydalen Oslo. Now they control the whole production line of their lead product candidate Radspherin. 2017 has been a good year for Oncoinvent. The company has relocated and built new office and laboratory facilities, grown from four to twelve employees, and raised new […]
PCI Biotech with pivotal study in 2018
Our portfolio company PCI Biotech (OSE: PCIB) got an early Christmas present this year. For some time, they have been in dialogue with the regulatory authorities in the US and Europe. On December 20th, they sent out the notice that they in 2018 will start a pivotal, randomized study on the development of fimaporfin in […]
ASH: Betalutin® shows strong clinical profile
Our portfolio company Nordic Nanovector ASA presented updated results from its LYMRIT 37-01 Phase 1/2 clinical study of Betalutin® (177Lu-satetraxetan-lilotomab) in patients with relapsed/refractory (R/R) indolent NHL (iNHL) at the 59th Annual ASH meeting. The updated data continue to highlight Betalutin®’s strong clinical profile as a single agent for treatment of R/R iNHL, and […]
Nordic Nanovector ASA – Results for the Third Quarter 2017
Nordic Nanovector is ready to initiate the pivotal Phase 2b study, PARADIGME, with Betalutin® in patients with relapsed, anti-CD 20 Ab-refractory FL (R/R FL), a high unmet medical need group, pending approval of the proposed trial design from regulatory authorities. Go to full presentation here PARADIGME is designed to generate the clinical data needed to […]